The adenomatous polyposis coli (APC) or b-catenin genes are frequently mutated in colorectal cancers, leading to activation of downstream genes with bcatenin/T-cell factor (Tcf)-responsive promoters. We have developed a gene therapy approach selectively targeting colorectal cancer cells in which b-catenin/ Tcf4 pathway is activated by using a recombinant adenovirus AdTOP-CMV-TK, which carries a herpes simplex virus thymidine kinase gene (HSV TK) under the control of a b-catenin/Tcf-response promoter linking to a minimum CMV promoter. AdTOP-CMV-TK and ganciclovir (GCV) treatment significantly suppressed the growth of human DLD-1 colon cancer cells in nude mice. Furthermore, no significant tumor suppression effect was observed in human hepatoma cell line SK-HEP-1, in which the b-catenin/Tcf pathway is not activated, as a control experiment. In summary, we demonstrated the selective targeting of colorectal cancers with activated bcatenin by AdTOP-CMV-TK and GCV treatment in animal models, as well as its therapeutic potential for colon cancer metastasized to liver.
The adenomatous polyposis coli (APC) or b-catenin genes are frequently mutated in colorectal cancers, leading to activation of downstream genes with bcatenin/T-cell factor (Tcf)-responsive promoters. We have developed a gene therapy approach selectively targeting colorectal cancer cells in which b-catenin/ Tcf4 pathway is activated by using a recombinant adenovirus AdTOP-CMV-TK, which carries a herpes simplex virus thymidine kinase gene (HSV TK) under the control of a b-catenin/Tcf-response promoter linking to a minimum CMV promoter. AdTOP-CMV-TK and ganciclovir (GCV) treatment significantly suppressed the growth of human DLD-1 colon cancer cells in nude mice. Furthermore, no significant tumor suppression effect was observed in human hepatoma cell line SK-HEP-1, in which the b-catenin/Tcf pathway is not activated, as a control experiment. In summary, we demonstrated the selective targeting of colorectal cancers with activated bcatenin by AdTOP-CMV-TK and GCV treatment in animal models, as well as its therapeutic potential for colon cancer metastasized to liver. Oncogene (2002 Oncogene ( ) 21, 8340 -8346. doi:10.1038 Keywords: APC; b-catenin; Tcf; colon cancer; adenovirus; thymidine kinase Mutation in the adenomatous polyposis coli gene (APC) or other components of the Wnt/b-catenin signaling pathway is believed to be a critical step in colon tumorigenesis. Loss of functional APC protein or constitutively stable b-catenin mutants (Morin et al., 1997) in cancer cells prevents degradation of the bcatenin protein through the ubiquitin/proteasome pathway. As a result, b-catenin protein is accumulated in the cytoplasm and nucleus of the cancer cells, leading to hyperactivation of downstream target promoters of the Wnt/b-catenin signaling pathway. The b-catenin protein does not bind DNA by itself; rather, it forms a bipartite complex with the T-cell factor family transcription factors and activates bcatenin/TCF-responsive promoters (Bienz and Clevers, 2000) . Many transcription targets of the Wnt/b-catenin signaling pathway have been identified, including genes that are involved in tumorigenesis, such as CyclinD-1 (Tetsu and McCormick, 1999; Shtutman et al., 1999; Lin et al., 2000) , c-myc (He et al., 1998a) and metalloprotease (Crawford et al., 1999) .
Unlike other common types of human cancers that harbor mutations in diverse pathways, mutations in the APC of b-catenin gene have been identified in most of the colon cancers (70 -80%) studied so far (Goss and Groden, 2000; Polakis, 2000) . On the other hand, APC/b-catenin pathway is usually not activated in most normal tissues. Therefore, a therapeutic strategy targets this pathway could be applied to most patients with primary or metastatic colon cancer. Here we proposed a gene therapy approach that would selectively express a therapeutic gene in colon cancer cells but not liver by targeting Wnt/b-catenin pathway. During the period of this study, Chen and McCormick (2001) reported a similar strategy to target colon cancer cells by a b-catenin/Tcf-response promoter in tissue culture. In this article, we address a similar question and further extend our observations to animal models while improving the expression efficiency of a tumor-specific promoter.
As a part of this study, we have developed an adenoviral vector in which expression of the herpes simplex virus thymidine kinase (HSV-TK) gene is driven by a novel b-catenin/TCF-responsive promoter. HSV-TK converts the purine nucleotide analogues gangiclovir (9-[2-hydroxy-1(hydroxyethoxy)ethoxy[methylguanine, GCV) into monophosphorylated compound. Mammalian kinases can further convert this compound into nucleotide triphosphates that inhibit DNA replication and act as a chain terminator for DNA synthesis. However, the GCV is only a poor substrate for mammalian nucleotide monophosphate kinase (Melton and Knox, 1999) . In the absence of HSV-TK, GCV cannot be converted into monophosphorylated compound and therefore will not be able to inhibit DNA synthesis. Thus, GCV has been used as a prodrug to kill cancer cells in the gene therapy setting when the HSV-TK gene is used as a therapeutic gene. In colon cancer, the activated b-catenin/TCF-responsive promoter will drive the expression of HSV-TK, which converts pro-drug into active form and kills the cells. The tumor-killing efficiency of this system was enhanced not only by the improved promoter activity, but also bystander effects of HSV TK plus GCV treatment. We demonstrated that our system significantly suppressed the growth of human colon cancer cells in both tissue culture and nude mouse model, whereas the same regimen did not suppress growth of human hepatoma cells in the control experiment.
In order to test the hypothesis that colon cancer cells can be selectively killed by targeting b-catenin/TCF pathway with a responsive promoter, the activities of five sets of b-catenin/TCF-responsive promoters were compared in four cell lines. Two well-characterized colon cancer cell lines, SW480 and DLD-1, were selected for this study. In both of the cell lines, the APC gene is mutated and b-catenin levels are elevated. Chang liver and SK-HEP-1 cell lines were included in this study as controls. These two cell lines are derived from liver origins and exhibit a very low level of bcatenin/Tcf transcription activity (data not shown). Figure 1a indicates the structures of the five sets of bcatenin/TCF responsive promoters. All of the bcatenin/TCF responsive promoters were constructed by fusing three copies of b-catenin/TCF binding sites (wild type sequence in TOP and mutated one in FOP promoters) with minimal human or viral promoters. For instance, the minimal CMV promoter in the TOP-CMV construct contains only 90 bp core sequence of CMV promoter and is used to provide a basal level activity and the TOP sequences are enhancers responsive to b-catenin/TCF interaction. On the contrary, the full-length CMV promoter of the CMVLuc construct which contains 660 bp sequence is constitutively activated in most mammalian cells and usually represents the maximal promoter activity in the cells. The activities of the promoters were measured with luciferase assays and the results are indicated in Figure 1b . The constitutively active full-length CMV promoter served as positive control, and the activities of the tested promoter were expressed as the percentage of CMV promoter activity. Except for TOP-hTERT, all b-catenin/TCF-responsive promoters were selectively activated in colon cancer cell lines, as shown by the fact that their TOP/FOP ratios were much higher in the b-catenin activated colon cancer cells (SW480 and DLD-1) than liver-derived cells in which b-catenin is not activated (Chang liver and SK-HEP-1). However, TOP-CMV exhibited much higher activity than any other b-catenin/TCF-response promoters in the two colon cancer cell lines. Because of its high specificity and activity for the colon cancer cell lines, TOP-CMV promoter was used in the rest of this study.
In the next step, an adenoviral vector was selected as the gene delivery system and the HSV-TK as the therapeutic gene. Four adenoviral vectors, AdCMVluc, AdTOP-CMV-luc, AdCMV-TK, and AdTOP-CMV-TK were constructed. To test the activation of these adenoviral vectors by b-catenin/TCF signaling, stable transfectants of HEK 293 cells bearing hyperactive b-catenin mutant (293.bcat-10 and 293.bcat-12) or selection marker only (293.neo) were infected with AdCMV-luc and AdTOP-CMV-luc. As shown in Figure 2a , the activity of AdTOP-CMV-luc was much stronger in b-catenin-hyperactive cells than in cells with basal b-catenin activity in luciferase assay. This result indicated that the adenoviral vector AdTOP-CMV could still selectively target b-catenin-hyperactive cells. The ability of AdCMV-TK and AdTOP-CMV-TK adenoviral vectors to kill cells with different b-catenin levels was compared by an in vitro assay. The four cell lines were infected with adenoviruses and treated with GCV 24 h after viral infection, then once daily for 7 days. Finally, the cell viability was measured by MTT assay. As shown in Figure 2b , the color intensity in each well was proportional to the number of survival cells. Figure 2c showed the quantification of Figure 2b . Cells with elevated b-catenin levels, such as SW480 and DLD-1, were killed efficiently by infection with either b-catenin/TCF-responsive AdTOP-CMV-TK adenovirus or constitutively active AdCMV-TK adenovirus, serving as positive control, plus GCV treatment. However, only the positive control virus AdCMV-TK, not AdTOP-CMV-TK, plus GCV treatment efficiently killed SK-HEP-1 and Chang liver cells, which were derived from liver origin. These results indicated that AdTOP-CMV-TK plus GCV treatment could be used in gene therapy to selectively kill colon cancer with little effect on liver.
To test the effectiveness of AdTOP-CMV-TK/GCV in suppressing tumor formation in animals, an ex-vivo strategy was carried out. DLD-1 and SK-HEP-1 cells were infected with adenoviruses in vitro, harvested after 24 h, and then inoculated subcutaneously into nude mice. The animals received intraperitoneal GCV treatment daily for 10 days and the sizes of tumor The AdTOP-CMV-TK virus preferentially targets colon cancer cell lines in vitro. The adenoviral vectors were constructed by the AdEasy system (He et al., 1998b) . The transcription termination sequences from the pGL3-Basic (Promega) and pcDNA3 plasmids (Invitrogen, Carlsbad, CA, USA) were inserted into pShuttle plasmid in a tail-to-tail orientation to construct pShuttleGB.
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b-Catenin as a target for colon cancer KY Kwong et al were monitored twice per week. As shown in Figure 3a , both AdCMV-TK and AdTOP-CMV-TK viruses dramatically suppressed tumor growth with GCV treatment in DLD cells. However, the AdTOP-CMV-TK did not suppress SK-HE-1 tumor growth as efficiently as AdCMV-TK even in the combination of GCV treatment (Figure 3b ). These results, indicating that AdTOP-CMV-TK indeed selectively kills colon cancer, were consistent with the hypothesis that suicide gene expression driven by the TOP-CMVF promoter can effectively suppress the growth of tumors with APC mutations and that the tumor suppression effect is diminished in liver cells in which the b-catenin pathway is inactivated. In a recent report (Chen and McCormick, 2001 ), a similar gene therapy strategy targeting colon cancer by a b-catenin/TCF-response promoter was reported. In that study, the commonly used TOP-TK promoter was inserted into adenoviral vector AdWt-Fd to drive the expression of pro-apoptotic gene Fadd. The authors showed that TOP-TK promoter-containing AdWt-Fd could selectively kill colon cancer cells in tissue culture. Unlike their studies that have used HSV TK core promoter in the constructs, we combined minimal CMV promoter and b-catenin/TCF-responsive element as TOP-CMV promoter in the construct. This simple manipulation significantly improved the activity of the b-catenin/TCF-responsive promoter in the b-cateninhyperactive cell lines, while still keeping the specificity (Figure 1b) . The success of cancer gene therapy depends not only on the specificity, but also the expression level, of the therapeutic gene. Thus the TOP-CMV promoter may be a better choice than TOP-TK.
In addition to the improvement in promoter activity, we adopted a different therapeutic gene, thymidine kinase (TK), as well as GCV treatment, to further enhance the expected efficiency of this gene therapy. In the cells expressed by TK, GCV was converted into an active compound, which not only killed that cell but also neighboring ones by a bystander effect. As shown in Figure 3 , growth of colon cancers and hepatomas in the animal model was not influenced by infection of AdTOP-CMV-TK in the absence of GCV treatment. However, growth of the infected colon cancer cells, but not hepatoma cells, was significantly suppressed by GCV treatment.
Although mutations in APC gene are limited predominately to colon or rectal cancers, hyperactivity of b-catenin has been reported in other tumors like hepatocellular carcinomas, melanomas, pilomatricomas, breast cancer, etc. (de La Coste et al., 1998; Rubinfeld et al., 1997; Chan et al., 1999; Lin et al., 2000) . Since mutations in b-catenin gene also resulted in the activation of b-catenin/TCF-responsive promoters, the gene therapy system described here may also be applied to these tumors. In fact, the hepatocellular carcinoma cell line HepG2, in which b-catenin is mutated, was very sensitive to treatment with AdTOP-CMV-TK/GCV (data not shown).
In conclusion, we improved the activity of a bcatenin/TCF-responsive promoter and showed that such promoter was selectively activated in colon cancer cells. We also showed that the combination of AdTOP-CMV-TK adenovirus and GCV treatment selectively killed b-catenin-hyperactive colon cancer cells, but not liver cells with low b-catenin activity, in both tissue culture and animal model. Thus, our work demonstrates that this approach may have therapeutic potential for the treatment of metastatic colon cancer in the liver. Human DLD-1 colon cancer cells were infected with 25 MOI of adenoviral vectors in serum free medium. Six to 12 h after adenoviral infection, equal volumes of medium supplemented with 10% FBS were added to the infected cells, which were then incubated at 378C overnight. At 24 h after adding the virus, the cells were trypsinized and inoculated subcutaneously into nude mice with 2610 6 DLD-1 cells per mouse. One day after inoculation of cancer cells, the mice in treatment groups received daily intraperitoneal injection of 2 mg of GCV in 0.5 ml 0.9% saline (approximately, 100 mg/kg body weight) for 10 consecutive days. In two independent experiments, DLD-1 tumors in control groups reached 2 cm in diameter after 4 weeks and were killed in accordance with institutional animal policy. The tumors were dissected and their weights measured. Results from the two experiments were pooled and are shown in the same diagram. (b) An independent experiment was performed with human SK-HEP-1 hepatoma cells. Each mouse was inoculated with 5610 6 of SK-HEP-1 cells subcutaneously. Other steps were the same as in (a)
